摘要
目的比较足叶乙甙软胶囊(VP-16)与拓扑替康(TPT)二线方案治疗晚期或复发食管小细胞癌的疗效和毒副作用。方法选择2002年1月至2010年1月年收治的进展或复发食管小细胞癌患者共41例,按治疗方法不同随机分为VP-16(n=21)和TPT组(n=20),VP-16组患者口服VP-16软胶囊100mg,连续14d,3周为一周期;TPT组静脉滴注TPT(1.25mg/m2),连续5d,每3周为1周期;每组患者均至少完成2周期化疗,对两组患者的疗效及不良反应进行对比分析。结果 VP-16组化疗客观有效率为23.8%,中位疾病进展时间3个月,中位生存时间40周,1年生存率为42.9%;TPT组客观有效率为15.0%,中位疾病进展时间3个月,中位生存时间38周,1年生存率35.0%;客观有效率及生存率比较两组无显著性差异(P>0.05)。VP-16组不良反应贫血、白细胞下降、血小板下降、恶心呕吐发生率显著低于TPT组,差异有统计学意义,而且VP-16组极少发生3～4级不良反应。结论口服VP-16软胶囊单药二线治疗晚期或复发食管小细胞癌疗效不低于TPT,并且不良反应发生率低,反应轻微。
Objective To compare the response and adverse effects of oral etoposide(VP-16) and intravenous drip of topotecan(TPT) as second-line chemotherapy for advanced or recurrent primary esophageal small cell cancer. Methods From January 2002 to January 2010, 41 patients with advanced or recurrent primary esophageal small cell cancer were randomly divided into 2 groups, and received oral VP-16(100 mg, d1-d14) or intravenous drip of TPT(1.25 mg/m2, d1-d5) respectively with every 3 weeks as one cycle. Every patient received chemotherapy for at least 2 cycles. Response and adverse effects were compared between the two groups. Results The objective response rates were 23.8% and 15.0%, median survival times 40 and 38 weeks, 1-year survival rates 42.9% and 35.0% respectively in VP-16 and TPT groups. There were no significant differences in response rate and 1-year survival rate between the two groups(P>0.05). The incidences of adverse effects including anemia, leucopenia, thrombocytopenia, and nausea and vomiting in VP-16 group were significantly lower than those in TPT group. Less 3-4 grade adverse effects occurred in VP-16 group. Conclusions The efficacy of VP-16 single-agent is not inferior to topotecan as second-line chemotherapy for patients with advanced or recurrent primary esophageal small cell cancer. The incidence of adverse effects of VP-16 is much lower than that of TPT.
出处
《消化肿瘤杂志（电子版）》
2010年第4期226-229,共4页
Journal of Digestive Oncology(Electronic Version)
关键词
足叶乙甙
拓扑替康
化疗
食管小细胞癌
Etoposide
Topotecan
Chemotherapy
Esophageal small cell cancer
